Provista Diagnostics

The company has also joined the Cancer Moonshot program, working within its Blood Profiling Atlas Project on pre-analytical variation in molecular tests.

The company is expanding test availability from its initial clinical study partners while preparing to launch clinical utility and health economic studies.

The customizable, programmable antibody array has the proteins synthesized on it from cDNA and looks at a broader range of HPV subtypes than ever before.

The firm plans to use the money to commercially develop its proteomic diagnostics, as well as for management hires and general corporate purposes.

The markers could help clinicians reduce the use of invasive procedures when evaluating lesions detected via CT scans, a major need in lung cancer treatment.

The proteomics-based diagnostics firm will use proceeds from the financing for continued commercial development, prospective clinical trials, and other purposes. 

The firm, which previously raised $6 million, said there were 24 investors in the private offering of equity financing.

NEW YORK (GenomeWeb) – Provista Diagnostics said today that its Scottsdale Ariz.-based CLIA-certified laboratory has received accreditation from the College of American Pathologists.

NEW YORK (GenomeWeb) – Provista Diagnostics today announced it has expanded a licensing deal for certain biomarkers and autoantibody technologies identified by researchers at the Biodesign Institute of Arizona State University.

NEW YORK (GenomeWeb) – With a fresh round of funding in hand, Provista Diagnostics is moving ahead with a pair of clinical trials for its dtectDx-Breast proteomic breast cancer diagnostic.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.